These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 20836670)

  • 21. Clinical trials referral resource. Primary central nervous system tumors.
    Cheson BD; Kaplan RS; Phillips PH
    Oncology (Williston Park); 1994 Oct; 8(10):51-2, 55. PubMed ID: 7803215
    [No Abstract]   [Full Text] [Related]  

  • 22. Everolimus for tumor recurrence after surgical resection for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Franz DN; Agricola KD; Tudor CA; Krueger DA
    J Child Neurol; 2013 May; 28(5):602-7. PubMed ID: 22805244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Everolimus for astrocytomas in tuberous sclerosis complex.
    Geoerger B; Blockus H
    Lancet; 2013 Jan; 381(9861):95-6. PubMed ID: 23158521
    [No Abstract]   [Full Text] [Related]  

  • 24. Optic nerve tumor in tuberous sclerosis complex is not responsive to sirolimus.
    Sparagana SP; Wilkes DC; Thompson CE; Bowers DC
    Pediatr Neurol; 2010 Jun; 42(6):443-6. PubMed ID: 20472200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma.
    Oudard S; Medioni J; Aylllon J; Barrascourt E; Elaidi RT; Balcaceres J; Scotte F
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):705-17. PubMed ID: 19496707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Individualized therapy and outcomes of microsurgery, radiotherapy, and chemotherapy for astrocytoma].
    Zhou WN; Chen ZP; You C; Mu YG; Sai K; Zhang JY; Zhang XH; Cheng JJ; Xu HC
    Ai Zheng; 2004 Nov; 23(11 Suppl):1555-60. PubMed ID: 15566679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CDKs as therapeutic targets for the human genetic disease tuberous sclerosis?
    Rosner M; Dolznig H; Fuchs C; Siegel N; Valli A; Hengstschläger M
    Eur J Clin Invest; 2009 Dec; 39(12):1033-5. PubMed ID: 19744185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2).
    Fukushima T; Yamamoto M; Ikeda K; Tsugu H; Kimura H; Soma G; Tomonaga M
    Anticancer Res; 1998; 18(5D):3965-70. PubMed ID: 9854511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Tuberous sclerosis].
    Metsähonkala L; Valanne L; Anttonen AK
    Duodecim; 2013; 129(17):1779-87. PubMed ID: 24159711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluating temsirolimus activity in multiple tumors: a review of clinical trials.
    Dancey JE; Curiel R; Purvis J
    Semin Oncol; 2009 Dec; 36 Suppl 3():S46-58. PubMed ID: 19963100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models.
    Lee L; Sudentas P; Donohue B; Asrican K; Worku A; Walker V; Sun Y; Schmidt K; Albert MS; El-Hashemite N; Lader AS; Onda H; Zhang H; Kwiatkowski DJ; Dabora SL
    Genes Chromosomes Cancer; 2005 Mar; 42(3):213-27. PubMed ID: 15578690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Everolimus in clinical practice--renal transplantation.
    Pascual J
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii18-23. PubMed ID: 16815852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuro-oncology: a selected review of ASCO 2011 abstracts.
    Chamberlain MC
    Expert Rev Neurother; 2011 Oct; 11(10):1371-7. PubMed ID: 21955193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. mTOR in tuberous sclerosis and other neurological disorders.
    Franz DN
    Epilepsia; 2007 Aug; 48(8):1630-1; author reply 1632-4. PubMed ID: 17692052
    [No Abstract]   [Full Text] [Related]  

  • 35. The effects of everolimus on tuberous sclerosis-associated lesions can be dramatic but may be impermanent.
    Miller JM; Wachsman A; Haker K; Majlessipour F; Danielpour M; Puliyanda D
    Pediatr Nephrol; 2015 Jan; 30(1):173-7. PubMed ID: 25194630
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The evolving experience using everolimus in clinical transplantation.
    Formica RN; Lorber KM; Friedman AL; Bia MJ; Lakkis F; Smith JD; Lorber MI
    Transplant Proc; 2004 Mar; 36(2 Suppl):495S-499S. PubMed ID: 15041395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic targeting of mTOR in tuberous sclerosis.
    Sampson JR
    Biochem Soc Trans; 2009 Feb; 37(Pt 1):259-64. PubMed ID: 19143643
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Everolimus for astrocytomas in tuberous sclerosis.
    Mukherjee D; Sarmiento JM; Ly D; Nuno MA; Patil CG
    Lancet; 2013 Apr; 381(9874):1274-5. PubMed ID: 23582392
    [No Abstract]   [Full Text] [Related]  

  • 39. Safety of Everolimus in Patients Younger than 3 Years of Age: Results from EXIST-1, a Randomized, Controlled Clinical Trial.
    Jóźwiak S; Kotulska K; Berkowitz N; Brechenmacher T; Franz DN
    J Pediatr; 2016 May; 172():151-155.e1. PubMed ID: 26858193
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chloroquine in glioblastoma--new horizons for an old drug.
    Munshi A
    Cancer; 2009 Jun; 115(11):2380-3. PubMed ID: 19326448
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.